Nonprofit Manufacturer Could Keep Generic Drug Costs Down

Share this content:
Nonprofit Manufacturer Could Keep Generic Drug Costs Down
Nonprofit Manufacturer Could Keep Generic Drug Costs Down

WEDNESDAY, May 16, 2018 (HealthDay News) -- A nonprofit manufacturer could help keep generic drug prices down and maintain their supply, according to a perspective piece published in the May 17 issue of the New England Journal of Medicine.

Dan Liljenquist, J.D., from Intermountain Healthcare in Salt Lake City, and colleagues discuss generic drug market failure, whereby a generic drug manufacturer increases the drug price, which can compromise care.

The authors note that other manufacturers do not enter the seemingly lucrative generic drug market partly because of the initial investment required and cost of obtaining U.S. Food and Drug Administration approval. In addition, there is concern that once a second drug is approved for the condition, the manufacturer of the original generic will reduce the price of its product. One solution is establishment of a nonprofit generic drug manufacturer with the aim of producing affordable versions of essential drugs and ensuring a stable supply. A consortium of hospitals and health plans is currently developing a nonprofit generic drug manufacturer named Project Rx. The nonprofit manufacturer, which has a legal constraint that it cannot distribute earnings, will pursue a cost-plus strategy, generating enough revenue to cover costs and maintain a limited surplus for financial viability rather than profit maximization.

"We believe that Project Rx may drive other nonprofit and for-profit manufacturers to enter generic-drug markets, compete among themselves, and collectively improve market efficiency and broaden access to generic drugs," the authors write.

One author disclosed serving as a volunteer on the advisory committee of Project Rx.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths